Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesHot NewsMost Read NewsRecomm.Business LeadersCalendar 

Boehringer Ingelheim GmbH : Boehringer Ingelheim and Funxional Therapeutics announce acquisition of Funxional’s FX125L and the somatotaxin portfolio to treat inflammation

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/23/2012 | 11:04am CEST

Ingelheim, Germany and Cambridge, UK - 23 July 2012 Today, Boehringer Ingelheim, one of the world's leading pharmaceutical companies, and Funxional Therapeutics, a clinical-stage, asset-centric, private company, announced an agreement under which Boehringer Ingelheim will acquire the global rights to Funxional Therapeutics' FX125L compound and somatotaxin programme. FX125L is a small molecule to treat a broad range of inflammatory diseases and was recently studied in a Phase 2 clinical trial in patients. Boehringer Ingelheim will be responsible for all further research, development and commercialisation of FX125L. Financial details of the transaction were not disclosed.

"Boehringer Ingelheim is delighted to add another promising compound to its development pipeline of drugs for the treatment of respiratory disease, one of its most important therapeutic areas", said Prof. Klaus Dugi, Corporate Senior Vice President Medicine, "by acquiring the Funxional Therapeutics programme, we are looking forward to bringing a potential new therapy to patients, for instance those suffering from Asthma and COPD."

David Grainger, Founder and CSO of Funxional Therapeutics commented: "We are very pleased that the future development of FX125L and the somatotaxin programme will be now driven forward by Boehringer Ingelheim. They are a very impressive organisation and their people have the necessary knowledge, skills and experience to successfully develop FX125L."

Funxional Therapeutics was founded by David Grainger with initial investment from Index Ventures and Novo A/S in 2006. Ventech led the Series B financing. Index Ventures' partner and Chairman of the board, Michele Ollier said: "This acquisition is further validation of Index's business model and we congratulate the team who have delivered first class science and developed a very exciting molecule. They have done an extraordinary job of building this company."

Notes for Editors

About Somatotaxins
The somatotaxins are a new class of anti-inflammatory small molecules that exploit a new pathway discovered by FXT. This novel pathway is acting through the type-2 somatostatin receptor involved in the resolution of inflammation, and disrupted in chronic inflammatory diseases including asthma, COPD and rheumatoid arthritis. FXT's portfolio of somatotaxins exploit this pathway to deliver broad and potent anti-inflammatory activity, with different compounds optimised for topical, parenteral and oral delivery.

About Funxional Therapeutics
Funxional Therapeutics Ltd (FXT) is a privately held, clinical stage pharmaceutical company based in Cambridge, UK.

FXT's focus is on novel anti-inflammatory therapies that exploit a new pathway discovered by FXT. The lead product (FX125L, an orally available, once-daily small molecule which belongs to the new class of somatotaxins) has completed several Phase I studies in the USA. Attractive efficacy compared to existing therapeutic options, together with an adequate safety profile and dosing convenience, all position FX125L for clinical and commercial differentiation, with the potential eventually to become the first line therapy in major inflammatory diseases. Funxional Therapeutics was founded in 2005 based on intellectual property developed by Dr David Grainger and his colleagues at Cambridge University, in collaboration with Ipsen, a global specialty-driven pharmaceutical company targeting debilitating diseases in neurology, endocrinology, uro-oncology and hemophilia. Index Ventures and Novo A/S provided first round funding to initiate research and development activities. Further funding was led by Ventech.

About Boehringer Ingelheim
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about 13.2 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news
Date Title
12:46a LONESTAR WEST : Announces Q1 2017 Financial Results
12:45a LONESTAR WEST : Announces Q1 2017 Financial Results
12:44a CLAROCITY CORPORATION : Announces Unaudited CAD $1.2 Million Revenue for April 2017
12:43a COST SAVING OPPORTUNITIES FOR THE GLOBAL SEM SERVICES MARKET : Technavio
12:38a WULING MOTORS : to buy equipment at Rmb53.67m
12:38a COSCO SHIPPING DEVELOPMENT : SHIP Dev to add Rmb1.76bn in China Bohai Bank
12:36a MINCO : Reports First Quarter 2017 Financial Results
12:36a MINCO : 2017 Q1 Management's Discussion and Analysis
12:35a TIGER BRANDS : to be vigilant on continent
12:34a DAIMLER : Mercedes-Benz SA embraces VR technology
Latest news
Advertisement
Hot News 
-2.69%Italy lags sluggish European shares as political worries weigh
-30.23%ALLIED IRISH BANKS : Ireland must make call on AIB IPO in next 10 days -minister
0.43%CHEUNG KONG PROPERTY : Hong Kong property cooling moves set to fail as shadow lenders fill the gap
-0.47%VOLKSWAGEN : EU ministers agree car approval rules after dieselgate
0.30%BAYERISCHE MOTOREN WERKE : BMW says shortage of parts from Bosch hampers production
Most Read News
06:00p Peak Files 2017 First Quarter Results and Operating Highlights
06:11p SAO CARLOS EMPREENDIMENTOS E PART : Notice to the Market - Sale of the Totality of São Carlos´ stake at Mykonos Building
06:32p WELL-COVERED : Carthage quilting group keeps newborns warm
06:32p 1 WRLD VN : "One World’’ song to be taught in German schools
06:01p CANADIAN NATIONAL RAILWAY : MAY 29, 2017CN and TCRC-CTY reach tentative agreement on new labour contract for conductors in Canada
Most recommended articles
05/22 NOBLE : shares tumble after S&P ratings downgrade
05:01p TSX edges higher as financials gain ground
04:16pDJNEWS HIGHLIGHTS : Top Energy News of the Day
04:15pDJSUBSCRIBERS : USDA Crop Progress Data To Be Released Tuesday
03:53pDJAKZO NOBEL : Dutch Court Backs Akzo Nobel in Dispute With Elliott Management -- Update